



Emerging Therapies for PBC, NASH and End Stage Liver Disease Seminar Series-Houston, TX 2/27/2016

This activity was created to address the professional practice gaps listed below:

- Using current best practices for the diagnosis and treatment approaches for Primary Biliary Cirrhosis (PBC).
- Identifying the warning signs of Non-Alcoholic Steatohepatitis (NASH) along with emerging drugs that can slow disease progression.
- Applying new approaches and scientific research finding into treat End stage liver disease (ESLD).

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [11-3.82]	(0)	(0)	(2) 18.18%	(9) 81.82%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [11-3.82]	(0)	(0)	(2) 18.18%	(9) 81.82%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [10-3.90]	(0)	(0)	(1) 10.00%	(9) 90.00%

2. Please elaborate on your previous answers. (7)

It is good refresher. I had learned these things and they become vague.

better maintenance, e screening practices

learned new ideas and therapy for nash pbc

I was very impressed with the presentations and the speakers. I truly learned a lot.

I am relatively new to GI, so this course provided a nice review of ESLD, NASH, PBC in my role as a hepatology NP this information has re-enforced and broadened my knowledge base

Will screen and advise more on NASH.

3. Please evaluate the effectiveness of the speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Howard P. Monsour, Jr., MD [11-3.91]	(0)	(0)	(1)	(10)

			9.09%	90.91%
John Vierling, MD [11-3.91]	(0)	(0)	(1) 9.09%	(10) 90.91%
Maura Smith, AGACNP-CB [9-3.89]	(0)	(0)	(1) 11.11%	(8) 88.89%

4. Please elaborate on your previous answers. (4)

good slides excellent speakers

The speakers were very thorough and informative with their presentations.

Did not see Maura's talk

very great speakers; thorough yet concise in order to cover multiple topics effectively

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (6)

I will be more alert to alkaline phosphatases than I was before.

better screening protocol

new meds for pbc

Testing patients and prescribing medications for treatment.

Improved overall knowledge, and will keep presented material in mind when formulating treatment plan

Provide resources to review and access protocols and standard of care information

6. How certain are you that you will implement this change?

(10)

Certain ⁽³⁻
30.00%)

Very Certain ⁽⁴⁻
40.00%)

Maybe ⁽¹⁻
10.00%)

N/A ⁽²⁻
20.00%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (6)

HCV & HBV Rx

Treatment of end stage liver disease. Balancing hyponatremia, hepatic encephalopathy, volume depletion, renal failure. They are difficult patients' to take care of.

nash

Autoimmune Hepatitis

Autoimmune hepatitis

Pancreatitis, IBD

8. Were the patient recommendations based on acceptable practices in medicine?

(10)

Yes (10-

100.00%)

10. Do you think the presentation was without commercial bias?

(10)

Yes (10-
100.00%)

12. Please provide any additional comments you may have about this educational activity. (4)

Very good. Just be sure computers and projectors are OK before starting educational activity

Wonderful presentation with a delicious meal.

Great conference

Overall very good educational activity. I enjoyed having a small group. improvement in technology would be good i.e. able to use response system. I would attend this conference if offered again.

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.

Emerging Therapies for PBC, NASH and End Stage Liver Disease Seminar Series-Seattle, WA

3/5/2016

This activity was created to address the professional practice gaps listed below:

- Using current best practices for the diagnosis and treatment approaches for Primary Biliary Cirrhosis (PBC).
- Identifying the warning signs of Non-Alcoholic Steatohepatitis (NASH) along with emerging drugs that can slow disease progression.
- Applying new approaches and scientific research finding into treat End stage liver disease (ESLD).

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [27-3.85]	(0)	(0)	(4) 14.81%	(23) 85.19%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [27-3.89]	(0)	(0)	(3) 11.11%	(24) 88.89%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [27-3.85]	(0)	(0)	(4) 14.81%	(23) 85.19%

2. Please elaborate on your previous answers. (9)

None

better workup of associated liver diseases

The information presented impacted my understanding of the standatd treatments for nash, nafld, pbc, and pcs.

This seminar series was wonderful. I was able to build on a lot of the knowledge case I already had as a nurse.

The Class was very informative

Excellent coverage of all topics.

I am new to hepatology and this seminar provided and relaxed environment to learn vas information in a short period of time.

The speakers at this CME were very knowledgable, well versed, experienced, and open to questions. I learned a tremendous amount from this lecture series.

3. Please evaluate the effectiveness of the speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Kris Kowdley, MD [27-3.96]	(0)	(0)	(1) 3.70%	(26) 96.30%
Robert Carithers, MD [27-3.74]	(0)	(0)	(7) 25.93%	(20) 74.07%
Ann Croghan, PA-C [27-3.26]	(0)	(4) 14.81%	(12) 44.44%	(11) 40.74%

4. Please elaborate on your previous answers. (9)

None

Dr. Carithers' talk was very clear and effective. He is one of the best speakers that I have seen.

Friendly, interactive, brilliant

All presenters were knowledgeable about the content being presented.

You definitely need a microphone as during many of the discussions you could not hear some of the responses.

As always Dr Kowdley was great.

Ann Croghan is a nurse practitioner not a PA

Passion for the liver was evident in all of the speakers and this allowed the knowledge to be presented in a fun educational setting.

As above.

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (18)

None

a few areas will be changed

New algorithm for looking at liver dz

Use a new algorithm for evaluating liver dysfunction

Implement a new algorithm for evaluating liver disease

better workup of liver disease

Counseling patients with nafld to lose 3-5% of weight.

Better able to understand PBC and PSC.

As a nurse I will not be making any changes but the knowledge I Have gained will help me relay information to patients

Better knowledge of above topics for patient education.

Identifying more patients with NASH

consistent lab orders and follow up

new protocols in liver transplantation. trying different medications like obeticholic acid

All the providers will implement the information into the practice, we as nurses will do what ever the providers will order and back them up.

As a new liver transplant coordinator, this presentation was so valuable. It made sense of

so much of what we do in clinical practice.

It would be wonderful in the dining/snacks if there was a gluten free option.

Increase patient education and more easily assist in planning and coordinating patient care.

6. How certain are you that you will implement this change?

(23)

Very Certain ⁽¹⁴⁻
60.87%)

Maybe ⁽¹⁻
4.35%)

Certain ⁽⁷⁻
30.43%)

N/A ⁽¹⁻
4.35%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (13)

None

More information on success of newer Hep C meds
not at this time

Hep C

I was very happy with this course content as it was. It would be nice to have a section on HCC treatment.

N/A

Hepatitis C. Still see many new patients for Hep C

hep C , hep B and hep B in pregnancy, ESLD, chronic abd pain and functional bowel, nausea and vomiting

pruritis in primary biliary cirrhosis. Hepatitis C

NASH Knowing that there is an increase in this problem. I would like to do more study on NASH to be able to help patient's understand and be able to change there disease.

I would have loved to hear more about autoimmune hepatitis.

NASH since it has been an upcoming problem that we are seeing in many patients.

HBV - High population of HBV in Seattle area. Increased education will allow for better patient care.

8. Were the patient recommendations based on acceptable practices in medicine?

(26)

Yes ⁽²⁵⁻
96.15%)

No ⁽¹⁻
3.85%)

9. If you answered No on the question above, please explain which recommendation(s) were not based on acceptable practices in medicine? (1)

N/A

10. Do you think the presentation was without commercial bias?

(26)

Yes (24-
92.31%)

No (2-
7.69%)

11. If you answered No on the above question, please list the topics that were biased? (1)

N/A

12. Please provide any additional comments you may have about this educational activity. (10)

None

Many pre and post quiz were poorly worded. The questions were given after (below) the answer choices, yet the questions state the "following" instead of the "above" answers. Just not very impressed by careless preparation of the materials.

none - thank you for the opportunity to attend

I learned a lot. Thank you for putting on the Class.

Very good informative educational session, lot of pearls which were reviewed. I would like to see more of these 1 day sessions on weekends.

appreciate that it was close to my home, nice facility to have the presentation, wish parking would have been complimentary. cost me 15\$ for parking

No, the presentation was done so well and would love to go to another one.

Thank you!

This CME was very good and informative learned lots. Thank you

The lecture proved to be a Saturday well spent!

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.

Emerging Therapies for PBC, NASH and End Stage Liver Disease Seminar Series-Louisville, KY

3/12/2016

This activity was created to address the professional practice gaps listed below:

- Using current best practices for the diagnosis and treatment approaches for Primary Biliary Cirrhosis (PBC).
- Identifying the warning signs of Non-Alcoholic Steatohepatitis (NASH) along with emerging drugs that can slow disease progression.
- Applying new approaches and scientific research finding into treat End stage liver disease (ESLD).

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [21-3.81]	(0)	(0)	(4) 19.05%	(17) 80.95%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [21-3.62]	(0)	(3) 14.29%	(2) 9.52%	(16) 76.19%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [21-3.76]	(0)	(1) 4.76%	(3) 14.29%	(17) 80.95%

2. Please elaborate on your previous answers. (9)

Nice mix of data and practical clinical information

A lot of new information

great program; good review of established information as well as new therapies

PSC and PBC is not something that you find in routine lectures. It was great to get info on it.

new approach to the twists in treatments

Working in the clinic setting with the physicians, we can utilize this information along with the use of our new fibroscan in diagnosing and treating these disease entities.

good information overall. the fact that the slides were by someone other than the speakers was evident at times.

Improved diagnostic skills and ability to identify appropriate treatments or referrals to treatments for patients.

I am familiar with much of the current thinking.

3. Please evaluate the effectiveness of the speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Craig McClain, MD [20-3.80]	(0)	(0)	(4) 20.00%	(16) 80.00%
Matt Cave, MD [20-3.85]	(0)	(0)	(3) 15.00%	(17) 85.00%
Barbara Cave, APRN, FNP-BC [20-3.40]	(0)	(2) 10.00%	(8) 40.00%	(10) 50.00%

4. Please elaborate on your previous answers. (6)

Experienced faculty with good speaking style

All were great and interactive

simple & straight forward

Very experienced hepatologists.

Not sure what purpose Ms. Cave offered. She could have been very useful as a practicing nurse practitioner but felt she was added on as a "token mid level"

All of them know there subject matter well.

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (17)

NASH evaluation and management

Using different medications for Nash especially in diabetes

I will use the fibroscan

improved care and screening for NASH patient improved screening for PBC and PSC

I don't prescribe, but will help with patient teaching

W/U understanding the treatment limitations

Consideration of sodium when looking at MELD scores in consideration of earlier transplant evaluation

Surveillance

looking at sodium when considering MELD scores for faster transplant referral

work with physicians on lab results and medication therapys

The transplant surgeons and hepatologists will drive this but as a clinician we will monitor clinical outcomes as a result.

refer to transplant team and with education regarding liver diseases

Identifying patients earlier for diagnostic testing for PBC, primary sclerosing cholangitis, NASH. Improved Ability to use appropriate diagnostic tests.

Change in treatment of NASH

Consider Trental for NASH patients

Will consider early referral for Liver transplant. Will consider the possibility of AMA neg PBC more often.

a better understanding of transplants and the procedures of such

6. How certain are you that you will implement this change?

(19)

Certain (11-
57.89%)

Very Certain (8-
42.11%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (11)

Acute alcoholic hepatitis and update in hepatitis C treatment Use of TIPS, patient selection

Eosinophilic esophagitis

Assesing Fatty liver disease. It will help me understand more of how to determine if a patient has fatty liver disease and how to treat.

etoh hepatitis hepatitis c after treatment with new DAA

herbals and OTC drugs and how they help/hurt the liver

alcoholic hepatitis

Viral Hepapitis

any thing from a GI standpoint...would love to have more education/options for gastroparesis

Management of liver lesions

Hep C and B. Ongoing research about NAFLD, NASH especially with regard to etiology and treatment.

8. Were the patient recommendations based on acceptable practices in medicine?

(20)

Yes (20-
100.00%)

10. Do you think the presentation was without commercial bias?

(20)

Yes (18-
90.00%)

No (2-
10.00%)

12. Please provide any additional comments you may have about this educational activity. (9)

Excellent content, well presented, duration about right. Location not so good

Great meeting. It is good to talk about something other than Hepatitis C.

Enjoyed all talks thanks to all faculty

Always enjoyed these speakers Helped me in difficult situations in hepatology

very interesting presentations!

Very well organized

Excellent conference

Short and sweet yet full of useful information.
excellent, didactic as well as practical

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.

Emerging Therapies for PBC, NASH and End Stage Liver Disease Seminar Series-Los Angeles, CA

4/2/2016

This activity was created to address the professional practice gaps listed below:

- Using current best practices for the diagnosis and treatment approaches for Primary Biliary Cirrhosis (PBC).
- Identifying the warning signs of Non-Alcoholic Steatohepatitis (NASH) along with emerging drugs that can slow disease progression.
- Applying new approaches and scientific research finding into treat End stage liver disease (ESLD).

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [1-4.00]	(0)	(0)	(0)	(1)100%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [1-4.00]	(0)	(0)	(0)	(1)100%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [1-4.00]	(0)	(0)	(0)	(1)100%

2. Please elaborate on your previous answers. (1)

learned appropriate testing to order, right imaging studies to order

3. Please evaluate the effectiveness of the speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Tse-Ling Fong, MD [1-4.00]	(0)	(0)	(0)	(1)100%
Tram Tran, MD [1-4.00]	(0)	(0)	(0)	(1)100%
Lucy Mathew, FNP-BC [1-4.00]	(0)	(0)	(0)	(1)100%

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (1)

new protocols

6. How certain are you that you will implement this change?

(1)

Very Certain (1-100.00%)

8. Were the patient recommendations based on acceptable practices in medicine?

(1)

Yes (1-100.00%)

10. Do you think the presentation was without commercial bias?

(1)

Yes (1-100.00%)

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.
